Health Canada has authorized Eli Lilly’s new weight-loss pill, Foundayo, for adults with obesity and for overweight adults with at least one related health condition such as high blood pressure or sleep apnea.
Foundayo is taken once daily, unlike weekly GLP-1 injections. It is also approved to help treat Type 2 diabetes.
The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist. Because it is a smaller molecule than semaglutide and tirzepatide, it can be absorbed orally without being broken down by the digestive system.
Dr. Ehud Ur, an endocrinologist in Vancouver, said the pill appears to be just as effective, if not better, for weight loss compared to semaglutide and tirzepatide. However, he said he is still waiting for clinical trial results on whether orforglipron provides cardiovascular benefits like the injectable drugs.
The most common side effects are gastrointestinal issues, such as nausea and vomiting, similar to other GLP-1 medications.
Foundayo received Health Canada authorization on November 13. Eli Lilly expects the pills to be available in pharmacies in January.
Another GLP-1 pill, Novo Nordisk’s Rybelsus, is already available in Canada but is only approved for Type 2 diabetes, not weight loss. Novo Nordisk’s Wegovy pill is still awaiting Health Canada approval.
Both Foundayo and the Wegovy pill are already approved and available in the United States.

